Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?
Identifieur interne : 000622 ( Main/Exploration ); précédent : 000621; suivant : 000623Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?
Auteurs : Sébastien Nisole [France] ; Aure Saulnier ; Anne Gatignol [Canada]Source :
- Virologie (Montrouge, France) [ 1267-8694 ] ; 2020.
Descripteurs français
- KwdFr :
- Anti-inflammatoires (usage thérapeutique), Antiviraux (usage thérapeutique), Betacoronavirus (effets des médicaments et des substances chimiques), Cytokines (antagonistes et inhibiteurs), Cytokines (métabolisme), Humains (MeSH), Infections à coronavirus (immunologie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Pandémies (MeSH), Pneumopathie virale (immunologie), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie).
- MESH :
- antagonistes et inhibiteurs : Cytokines.
- effets des médicaments et des substances chimiques : Betacoronavirus.
- immunologie : Infections à coronavirus, Pneumopathie virale.
- métabolisme : Cytokines.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anti-inflammatoires, Antiviraux.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Humains, Pandémies.
English descriptors
- KwdEn :
- Anti-Inflammatory Agents (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Coronavirus Infections (virology), Cytokines (antagonists & inhibitors), Cytokines (metabolism), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (immunology), Pneumonia, Viral (virology).
- MESH :
- chemical , antagonists & inhibitors : Cytokines.
- chemical , metabolism : Cytokines.
- chemical , therapeutic use : Anti-Inflammatory Agents, Antiviral Agents.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- immunology : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Humans, Pandemics.
DOI: 10.1684/vir.2020.0843
PubMed: 32648548
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?</title><author><name sortKey="Nisole, Sebastien" sort="Nisole, Sebastien" uniqKey="Nisole S" first="Sébastien" last="Nisole">Sébastien Nisole</name><affiliation wicri:level="3"><nlm:affiliation>Institut de recherche en infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de recherche en infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Saulnier, Aure" sort="Saulnier, Aure" uniqKey="Saulnier A" first="Aure" last="Saulnier">Aure Saulnier</name><affiliation><nlm:affiliation>À titre personnel.</nlm:affiliation><wicri:noCountry code="no comma">À titre personnel.</wicri:noCountry></affiliation></author><author><name sortKey="Gatignol, Anne" sort="Gatignol, Anne" uniqKey="Gatignol A" first="Anne" last="Gatignol">Anne Gatignol</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire des interactions Virus-Cellule, Institut Lady Davis de recherches médicales ; Département de médecine, Département de microbiologie et immunologie, Université McGill, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Laboratoire des interactions Virus-Cellule, Institut Lady Davis de recherches médicales ; Département de médecine, Département de microbiologie et immunologie, Université McGill, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32648548</idno><idno type="pmid">32648548</idno><idno type="doi">10.1684/vir.2020.0843</idno><idno type="wicri:Area/Main/Corpus">000A34</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A34</idno><idno type="wicri:Area/Main/Curation">000A34</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A34</idno><idno type="wicri:Area/Main/Exploration">000A34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?</title><author><name sortKey="Nisole, Sebastien" sort="Nisole, Sebastien" uniqKey="Nisole S" first="Sébastien" last="Nisole">Sébastien Nisole</name><affiliation wicri:level="3"><nlm:affiliation>Institut de recherche en infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de recherche en infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Saulnier, Aure" sort="Saulnier, Aure" uniqKey="Saulnier A" first="Aure" last="Saulnier">Aure Saulnier</name><affiliation><nlm:affiliation>À titre personnel.</nlm:affiliation><wicri:noCountry code="no comma">À titre personnel.</wicri:noCountry></affiliation></author><author><name sortKey="Gatignol, Anne" sort="Gatignol, Anne" uniqKey="Gatignol A" first="Anne" last="Gatignol">Anne Gatignol</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire des interactions Virus-Cellule, Institut Lady Davis de recherches médicales ; Département de médecine, Département de microbiologie et immunologie, Université McGill, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Laboratoire des interactions Virus-Cellule, Institut Lady Davis de recherches médicales ; Département de médecine, Département de microbiologie et immunologie, Université McGill, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author></analytic><series><title level="j">Virologie (Montrouge, France)</title><idno type="ISSN">1267-8694</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (virology)</term><term>Cytokines (antagonists & inhibitors)</term><term>Cytokines (metabolism)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anti-inflammatoires (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Cytokines (antagonistes et inhibiteurs)</term><term>Cytokines (métabolisme)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (immunologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (virologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32648548</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1267-8694</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>06</Month><Day>01</Day></PubDate></JournalIssue><Title>Virologie (Montrouge, France)</Title><ISOAbbreviation>Virologie (Montrouge)</ISOAbbreviation></Journal><ArticleTitle>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?</ArticleTitle><Pagination><MedlinePgn>135-141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1684/vir.2020.0843</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nisole</LastName><ForeName>Sébastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut de recherche en infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saulnier</LastName><ForeName>Aure</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>À titre personnel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gatignol</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratoire des interactions Virus-Cellule, Institut Lady Davis de recherches médicales ; Département de médecine, Département de microbiologie et immunologie, Université McGill, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Syndrome respiratoire aigu sévère dû au coronavirus 2 (SRAS-CoV-2) : faut-il cibler le virus, la cellule ou la maladie ?</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Virologie (Montrouge)</MedlineTA><NlmUniqueID>9802575</NlmUniqueID><ISSNLinking>1267-8694</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32648548</ArticleId><ArticleId IdType="pii">vir.2020.0843</ArticleId><ArticleId IdType="doi">10.1684/vir.2020.0843</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>France</li></country><region><li>Languedoc-Roussillon</li><li>Occitanie (région administrative)</li></region><settlement><li>Montpellier</li></settlement></list><tree><noCountry><name sortKey="Saulnier, Aure" sort="Saulnier, Aure" uniqKey="Saulnier A" first="Aure" last="Saulnier">Aure Saulnier</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Nisole, Sebastien" sort="Nisole, Sebastien" uniqKey="Nisole S" first="Sébastien" last="Nisole">Sébastien Nisole</name></region></country><country name="Canada"><noRegion><name sortKey="Gatignol, Anne" sort="Gatignol, Anne" uniqKey="Gatignol A" first="Anne" last="Gatignol">Anne Gatignol</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000622 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000622 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32648548
|texte= Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32648548" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |